Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Series A generates impressive $104mm for Adaptimmune

Executive Summary

Adaptimmune Ltd. (developing T-cell therapies for cancer and infectious diseases) closed an oversubscribed Series A financing of $104mm. New Enterprise Associates led and was joined by other first-time backers OrbiMed Advisors, Wellington Management Co., Fidelity Biosciences, Foresite Capital Management, Ridgeback Capital Management, Novo AS, QVT, Rock Springs Capital, venBio Select, and Merlin Nexus, along with returning investors including the University of Oxford and others.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register